The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Palexia 50 mg film-coated tablets

50 milligram(s) Film-coated tablet

Grunenthal Pharma LtdPA2242/012/001

Main Information

Trade NamePalexia 50 mg film-coated tablets
Active SubstancesTapentadol hydrochloride
Strength50 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderGrunenthal Pharma Ltd
Licence NumberPA2242/012/001

Group Information

ATC CodeN02AX Other opioids
N02AX06 tapentadol


Licence Issued21/12/2010
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in schedule 2 to the Misuse of Drugs Regulations 2017.
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back